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Objectives: We describe rates of success for two-stage revision of prosthetic joint infection (PJI), including data
on reimplantation microbiology.
Methods: We retrospectively collected data from all the cases of PJI that were managed with two-stage revi-
sion over a 4 year period. Patients were managed with an antibiotic-free period before reimplantation, in order
to conﬁrm, clinically and microbiologically, that infection was successfully treated.
Results: One hundred and ﬁfty-two cases were identiﬁed. The overall success rate (i.e. retention of the prosthe-
sis over 5.75 years of follow-up) was 83%, but was 89% for ﬁrst revisions and 73% for re-revisions [hazard
ratio¼2.9, 95% conﬁdence interval (CI) 1.2–7.4, P¼0.023]. Reimplantation microbiology was frequently posi-
tive (14%), but did not predict outcome (hazard ratio¼1.3, 95% CI 0.4–3.7, P¼0.6). Furthermore, most
unplanned debridements following the ﬁrst stage were carried out before antibiotics were stopped (25
versus 2 debridements).
Conclusions: We did not identify evidence supporting the use of an antibiotic-free period before reimplantation
and routine reimplantation microbiology. Re-revision was associated with a signiﬁcantly worse outcome.
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Introduction
Arthroplasty improves the patient’s quality of life and is highly
cost effective.
1–3 Prosthetic joint infection (PJI) complicates up
to 2.5%
4 of the estimated 90000 primary arthroplasties per-
formed annually in England and Wales,
5 and presents a major
challenge to patients, physicians and funding agencies. PJI
does not generally respond to antibiotics alone, but can be
managed by ‘DAIR’ (debridement, antibiotics and implant reten-
tion), or by one- or two-stage exchange revisions.
6 Exchange
revision is the intervention of choice if the implant has become
loose.
7
A recent meta-analysis including 926 two-stage knee joint
revisions concluded there was an 82%–100% success rate, but
the reasons for variable success rates were not clear.
8 Success
rates described for two-stage exchanges of hip prostheses
ranged from 75% among 169 cases
9 to 90% among 99
cases,
10 29 cases
11 and 41 cases.
12
However, there are few descriptions of the clinical and micro-
biological parameters that predict treatment failure, and the role
of reimplantation microbiology remains unclear. We present 155
cases of PJI treated by two-stage revision, managed with stan-
dardized surgical and microbiological protocols
13 and detailed
clinical information. Our routine practice during this period was
to undertake reimplantation at least 2 weeks after stopping anti-
biotics. This was done, ﬁrstly, so that clinical failures after stop-
ping antibiotics would become evident before reimplantation
had taken place and, secondly, so that samples for microbial
culture taken at reimplantation would not be falsely negative
because of recent antibiotics.
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This was a retrospective series of all cases of PJI managed by two-stage
revision surgery in the Bone Infection Unit of the Nufﬁeld Orthopaedic
Centre, Oxford, UK between 1 January 1999 and 30 April 2003.
Cases were managed by infectious disease physicians and orthopaedic
surgeons in a multidisciplinary team. We established a registry and
included all cases of PJI using multiple data sources: histopathology
and outpatient parenteral antimicrobial therapy (OPAT) databases; hospi-
tal activity coding databases; systematically hand-searched diagnostic
details listed in outpatient clinic letters; and prospective capture of
patients attending follow-up outpatient appointments or readmitted to
our unit.
Following a review of the case notes, we excluded patients whose
primary management of infection was excision arthroplasty without an
intention to reimplant, single-stage revision surgery, DAIR or suppressive
antibiotic therapy without debridement.
Two researchers (N. G. and H. P.) extracted data from case notes of
included patients for entry into a Microsoft
w Access database. Data
were cleaned by a senior investigator (P. B.), who examined extreme
outlier observations and obvious inconsistencies in the entered data,
and then subsequently selected a random set of these case notes (total-
ling 10% of the case notes), independently extracted data and reconciled
the two extractions. Reconciling the differences among randomly
selected data conﬁrmed the accuracy of the primary extraction. The
hip and knee scores using the 0–48 Oxford scoring system
14 were
measured at the end of follow-up, a mean of 5.75 years after the original
surgery.
Case deﬁnition
Infection was deﬁned as those having a clinical syndrome of arthroplasty
infection (any of persistent inﬂammation in the tissues around the
implant, wound discharge or implant loosening) with one or more of
the following: bacterial growth of an indistinguishable organism from
two or more deep periprosthetic tissue samples; histology of peripros-
thetic tissues indicative of infection; or a persistent sinus tract. Patients
with no clinical or radiographic evidence of joint loosening were
managed with DAIR.
15 Multiple samples were taken for microbiological
culture, as previously described.
13 The histological diagnosis was made
on the basis of the degree of inﬁltration by neutrophil polymorphonuclear
leucocytes, as outlined in previous studies.
16–18
Deﬁnition of treatment failure
We deﬁned treatment failure as: (i) sinus drainage recurring after
reimplantation; (ii) a requirement for further revision surgery (irrespective
of the indication); or (iii) amputation of the affected limb. The require-
ment for ongoing antibiotics or further debridement was not considered
treatment failure per se.
Data collection
We collected data from the patient notes on patient demographics,
co-morbidities (diabetes, renal failure, immunosuppression, rheumatoid
arthritis, malignancy and smoking), the date of primary surgery,
symptom onset, clinical features at presentation and surgical ﬁndings,
microbiology, and antibiotic choice and duration. There was no
research-related contact with patients and informed consent was not
required (as advised by our institutional review board). All activity was
conducted in accordance with the Declaration of Helsinki, and national
and institutional standards.
Antibiotic management
After intraoperative sampling at excision of the infected implant, patients
received empirical intravenous (iv) vancomycin (1 g; continued as 1 g
initially 12 hourly, adjusted according to levels) plus 500 mg of merope-
nem 8 hourly (increased to 1 g 8 hourly for pseudomonads). Therapy
was rationalized once deﬁnitive culture results were obtained from the lab-
oratory. Meropenem was discontinued at 48 h if no aerobic Gram-negative
pathogens requiring treatment with a carbapenem had been cultured.
15,19
Intravenous antibiotic therapy was continued for 6 weeks with a
b-lactam or glycopeptide, according to the susceptibility proﬁles of cul-
tured organisms. It was not our practice to prolong antibiotic treatment
based on measurement of biomarkers, unless further debridements were
required, in which case iv antibiotic therapy was restarted after the deb-
ridements. If patients were suitable for OPAT, the preferred treatment
was with ceftriaxone (1 g daily) for most susceptible pathogens or with
teicoplanin for coagulase-negative staphylococci and methicillin-
resistant Gram-positive organisms. Patients with negative cultures were
treated with glycopeptides.
20 We used a carbapenem to treat Gram-
negative organisms that were resistant to cephalosporins or that were
associated with inducible resistance to cephalosporins. Oral antibiotics
were not used routinely, but patients experiencing side effects that pre-
cluded further iv therapy, or experiencing difﬁculties in maintaining iv
access, were switched to oral therapy to complete 6 weeks. Antibiotics
were stopped at 6 weeks, followed by a minimum 2 week antibiotic-free
period before reimplantation.
Surgical management
Atﬁrst-stagesurgery,sinuseswereexcisedandthesuperﬁcialcontaminated
layers discarded. Intraoperative samples for culture and histology were
taken of joint ﬂuid, joint capsule (hip), synovium (knee), infected collections
and membrane from each interface as prosthetic components were
removed. Each sample was obtained with separate instruments and
placed into separate containers for processing, as previously described.
13
The bone ends, medullary cavities and joint cavity were debrided of all
infected, necrotic and foreign material, following which the operative ﬁeld
waslavagedwithseverallitresofwarmsaline.Spacersofbonecementcon-
taining gentamicin were used routinely in the knee but rarely in the hip.
Where plastic surgery was used to achieve soft tissue cover, this was done
using medial gastrocnemius ﬂaps with skin grafting over the knee.
At second-stage surgery, a further set of specimens for culture and
histology was taken in the same manner prior to the implantation of a
new prosthesis. Antibiotic prophylaxis was not given until after the speci-
mens were taken. Gentamicin-impregnated cement was used for cemen-
ted implants and allograft bone was used if required. According to our
protocol, no pre-operative sampling was undertaken.
Analysis
We used STATA version 10 (Stata Corp., College Station, TX, USA) to run
Cox survival analyses. Data were censored from follow-up after recur-
rence of infection or when lost to follow-up. The endpoint for treatment
failure was as deﬁned above. Univariate analysis was conducted on
factors relevant to presentation or initial treatment. Subsequently, multi-
variate analysis was conducted for factors signiﬁcant or of borderline
signiﬁcance (P,0.1) on univariate analysis.
Results
Characteristics of the cohort
One hundred and ﬁfty-ﬁve cases of PJI treated by two-stage revi-
sion were identiﬁed. In three instances the case deﬁnition for
infection was not met and these were excluded from further
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570analysis. In the 152 that remained, the diagnosis was supported
by histological criteria in the vast majority (95%). Both micro-
biology and histology were positive in 56%. The diagnosis was
based on microbiological criteria alone in only 3% of cases.
One percent was included on the basis of a sinus tract alone,
despite negative histology and microbiology results (Table 1).
Half of the patients were .70 years old and 65% had one or
more co-morbidities. Most of the implants were .2 years old
(62%) and most patients had had symptoms for  3 months
Table 1. Patient demographics, operative and antibiotic management
Factor n %
Case deﬁnition
microbiological criteria 90 59
histological criteria 145 95
microbiology only 5 3
sinus without microbiology/histology 2 1
Age group (years)
20–50 8 5
50–,60 23 15
60–,70 46 30
70–,80 63 42
80 12 8
Gender
male 93 61
female 59 39
Joint
hip 71 46
knee 77 51
elbow 4 3
Co-morbidities
none 53 35
15 5 3 6
.14 4 2 9
Time since ﬁrst joint replacement
,90 days 4 3
90 days–,1 year 21 15
1–,2 years 31 22
2–,10 years 29 20
10 years 58 41
missing data 9 –
Length of symptoms
,3 months 37 32
3–,12 months 29 25
1 year 51 44
missing data 35 –
Previous revisions
06 2 4 5
14 6 3 4
.12 9 2 1
missing data 42 –
Referral route
tertiary referral 119 78
Oxfordshire patient 33 22
Microbiology
Staphylococcus aureus 27 18
Gram-negative rods 11 7
coagulase-negative staphylococci 45 30
streptococci 11 7
culture negative 62 41
Continued
Table 1. Continued
Factor n %
Debridements between stages
no second stage 6 4
0 124 82
11 8 1 2
23 2
31 1
Muscle ﬂaps
none 136 87
at ﬁrst stage 9 6
after ﬁrst stage 7 5
Periprosthetic fracture
absent 140 95
present 12 5
Gap between stages
,56 days 8 4
56–,120 days 70 46
120 days–,1 year 54 36
1–,2 years 10 7
2 years 1 1
no second stage 6 4
Outcomes (median follow-up¼5.75 years)
a
not reimplanted 6 4
early excision 3 1
retained 126 83
late excision 15 10
late amputation 2 1
Antibiotics between stages
,4 weeks iv 48 32
4 weeks iv 103 68
missing 1 –
Antibiotics after reimplantation
none 88 58
,1 week 9 6
1 week–,6 weeks 13 15
6 weeks–,6 months 8 5
6 months–,1 year 6 4
1 year 28 18
aLate excision includes any operation, after 6 months, that excises the
implant, including excision arthroplasty and one- or two-stage
re-revisions.
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JAC(69%). Previous revisions were common (55%) and were over-re-
presented among tertiary referrals from other centres. Of the
patients with complete data for numbers of re-revisions and
referral source, 62% of 89 tertiary referrals were re-revisions,
compared with 29% of the 28 patients from the Oxford area,
P¼0.002. Of 20 patients with more than one previous revision,
all were tertiary referrals.
Infecting organisms
The most common infecting organisms were coagulase-negative
staphylococci and culture-negative infection was surprisingly fre-
quent (41%), despite 93% of cases having at least a 2 week
antibiotic-free gap before primary sampling (Table 1). Among
the 11 patients who did not have a 2 week antibiotic-free gap,
8 were culture positive.
Culture-negative infection was not associated: (i) with auto-
immune disease (38% of 26 patients, compared with 41% of 126
patients without, P¼0.4); (ii) with age of implant (36% of 56
patients with implants ,2 years old, compared with 40% of 87
with implants  2y e a r so l d ,P¼0.6); (iii) with tertiary referral (37%
of 119 patients, compared with 52% of local referrals, P¼0.16); or
(iv) with previous revisions (48% of 62 primary implants versus
33% of 75 previously revised implants, P¼0.1). Culture-negative
infection was, however, more common in knees than hips (28% of
71 hip joints versus 51% of 77 knee joints, P¼0.008).
Operative management
The operative course was complicated for some patients: 11%
required a muscle ﬂap; 15% required a further debridement
between the ﬁrst and second stages; and a periprosthetic frac-
ture occurred in 5% (Table 1). The second stage (i.e. reimplanta-
tion) was more likely to be delayed past 120 days if these
complications occurred (38% were delayed without compli-
cations, 70% with, x
2¼12, P,0.0005).
Outcomes
Of those who began on the two-stage treatment pathway, 96%
eventually progressed to reimplantation. There were no peri-
operative deaths. One patient was discharged to long-term insti-
tutional care, ﬁve patients (3%) required transfer to rehabilitation
facilities after reimplantation and the rest (96%) were discharged
home.
Although 96% proceeded to reimplantation, loss of the pros-
thesis or of the limb was subsequently recorded in a further 12%
over the mean follow-up time of 5.75 years, suggesting an
overall success rate of 83%. In two instances, amputation was
undertaken. In two instances, debridements with subsequent
long-term retention of the prosthesis were performed; this was
not considered treatment failure.
Oxford hip and knee scores were available on 76 (50%) of the
patients, measured at a median of 5.75 years after surgery. The
median score was 27, with an interquartile range of 21–38.
Factors associated with implant survival
On univariate Cox regression, only three factors were signiﬁcantly
associated with an increased rate of implant failure: younger age
of the patient; more time elapsed since the original surgery; and
0.00
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Figure 1. Kaplan–Meier plot showing survival of implants by older
( 70 years) versus younger (,70 years) patient age.
Table 2. Factors inﬂuencing outcomes, univariate Cox regression
Factor HR 95% CI P value
Age of patient (per 10 years) 0.58 0.4–0.9 0.008
Age of implant (per 5 years) 1.36 1.1–1.8 0.019
Length of symptoms 90 days 0.61 0.2–2.3 0.46
Length of symptoms 1 year 0.94 0.4–2.7 0.9
Gender 1.6 0.7–3.5 0.3
Co-morbidity 0.9 0.6–1.4 0.6
Knee (versus hip) 1.4 0.6–3.1 0.4
Tertiary referral 1.1 0.4–2.8 0.8
Previous revision 2.9 1.2–7.4 0.023
Muscle ﬂap required 0.97 0.3–3.3 0.97
Fracture occurred 2.2 0.8–6.5 0.14
Gram-negative bacilli 0.6 0.1–4.7 0.7
Streptococci 0.4 0.1–3.1 0.4
Staphylococcus aureus 0.35 0.1–1.5 0.2
Coagulase-negative staphylococci 1.3 0.6–3.0 0.5
Culture negative 1.7 0.8–3.6 0.2
Reimplantation microbiology 1.3 0.4–3.7 0.6
4 weeks of iv antibiotics between stages 0.78 0.4–1.7 0.5
1 week of antibiotics after second stage 0.73 0.3–1.6 0.4
HR, hazard ratio; CI, conﬁdence interval.
Table 3. Factors inﬂuencing outcomes, multivariate Cox regression
Factor HR 95% CI P value
Age of patient (per 10 years) 0.6 0.4–0.9 0.02
Time since ﬁrst implant (per 5 years) 1.0 0.8–1.4 0.5
Previous revision 2.9 1.1–7.7 0.032
HR, hazard ratio; CI, conﬁdence interval.
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572a greater number of previous revisions (Table 2). On multivariate
analysis, the effect of time since ﬁrst joint replacement was not
signiﬁcant and the effect of time elapsed appeared to be
accounted for by the number of previous revisions (Table 3).
The survival plots of the two factors that remained signiﬁcant
on multivariate analysis show that patient age may have a con-
stant effect over time (Figure 1), but that the effect of previous
revisions on implant survival is mostly mediated in the ﬁrst
6 months (Figure 2).
Re-revisions
The overall success rate was 83%, but was 89% for ﬁrst revisions
and 73% for re-revisions. In addition to being associated with
greater failure rates, re-revisions were also associated with
increased use of muscle ﬂaps (16% versus 4%, P¼0.03), and
tendencies towards an increased rate of periprosthetic fracture
(11% versus 6%, P¼0.4) and an increased rate of unplanned
debridements between stages (20% versus 11%, P¼0.18). The
composite complication rates for any of these events were
41% versus 20% (P¼0.015). However, none of these compli-
cations was independently associated with a worse outcome
and so did not explain the worse outcome of re-revision
(Table 2). Re-revision was also associated with more long-term
oral antibiotic use after reimplantation (40% versus 19%,
P¼0.02).
Reimplantation microbiology
Routine cultures sent at reimplantation were positive in 14% of
patients. Coagulase-negative staphylococci were most com-
monly isolated (11%). Staphylococcus aureus (3%) and coliforms
(2%) were less common. The same organism, determined by
comparing species and antibiotic susceptibility patterns, was iso-
lated at both excision and reimplantation in four cases (3%). In
10 cases (6%) a different organism was isolated and in 7
cases (5%) reimplantation cultures were positive following nega-
tive cultures at the ﬁrst stage.
There was no evidence that positive reimplantation cultures
were associated with worse outcome (Table 2 and Figure 3),
but more antibiotics were given to these patients. Ninety-one
percent of patients with positive reimplantation cultures were
treated with antibiotics, compared with 18% of those with nega-
tive cultures. Very prolonged antibiotics (i.e. .1 year) were given
to 57% of those with positive reimplantation cultures, compared
with 12% of those with negative cultures.
Reimplantation was preceded by a 2 week antibiotic-free
period in 88% of cases. Microbiology was positive in 3 of 18
patients (16%) without a 2 week antibiotic-free period, com-
pared with 18 out of 134 (13%) with a 2 week antibiotic-free
period. Reimplantation cultures were more often positive in
knees than in hips (21% versus 6%, P¼0.01).
Unplanned debridements were rarely required during the
antibiotic-free period (two instances only). In contrast, 25
unplanned debridements were carried out before the antibiotic-
free period.
Discussion
We report 152 cases of PJI managed by two-stage revision, with
an overall success rate of 83% over a median follow-up of
5.75 years. This is within the range of reported success
rates,
8,10,12 but is confounded by the very high rate of tertiary
referrals requiring re-revisions in this cohort. Re-revision was
associated with three times the risk of implant failure in
time-to-event Cox regression analysis, with success rates of
89% for ﬁrst revisions and 73% for re-revisions.
Re-revision was also associated with a more complicated sur-
gical course, with a greater requirement for muscle ﬂaps to
manage soft tissue problems, more frequent unplanned debride-
ment before reimplantation, more frequent periprosthetic
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Figure 2. Kaplan–Meier plot showing survival of implants by primary
implant versus previously revised implants.
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Figure 3. Kaplan–Meier plot showing survival of implants by
reimplantation culture results.
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JACfractures and more often required prolonged antibiotics after
reimplantation. However, on univariate analysis, none of these
factors was associated with increased failure rates except time
since original surgery. On multivariate analysis, re-revision was
the stronger factor. This suggests that poor outcome was associ-
ated with re-revision per se and was not confounded by these
other measured factors.
Re-revision for infection was associated with poorer outcomes
in previous studies. In a study of 64 two-stage revisions for
patients with infected knee replacements, the success rate was
92% for ﬁrst revision and 41% if previous surgery had been con-
ducted (including previous revision).
21 In a study of 24 re-revised
knee replacements, only one prosthesis remained uninfected at
2 years,
22 and in a study of 11 re-revised hip replacements,
only 3 remained infection free.
23
Our data demonstrate that re-revision surgery is more
complex and less often successful than ﬁrst revisions for infec-
tion. It is therefore particularly important that infection is con-
sidered and adequately managed at the ﬁrst revision.
Nevertheless, in our dataset we found a relatively high success
rate for re-revisions (73%), using a multidisciplinary team
approach, with joint revision surgeons, plastic surgeons and
infectious diseases physicians using rigorous diagnostic and
treatment protocols.
Younger age was also independently associated with worse
outcome. This may be because symptoms of implant failure
are more likely to be reported or acted on in younger patients,
leading to a surveillance bias, or that the implants are exposed
to more mechanical stress because of the younger patients’
life styles.
Culture-negative infection has been identiﬁed as a particular
challenge in managing PJI
24 and it is therefore encouraging
that, despite being a common problem in our cohort, it was
not associated with a poorer outcome. This may be because
non-cultured organisms are low-grade or present in low
numbers, or were susceptible to our empirical antibiotic
therapy (glycopeptides in our cohort). Previous reports of culture-
negative PJI found a lower prevalence (11%),
24 but this study
included PJI managed by a variety of protocols. In our centre,
only 3% of the more acute infections managed by DAIR were
culture negative,
15,19 compared with 41% in this cohort. It may
be that the chronic infections referred for two-stage revisions
are more likely to be culture negative. Most patients (95%) had
a histological conﬁrmation of the diagnosis of infection. Some
of the organisms responsible might have been cultured had we
used longer incubation periods or techniques designed to
disrupt bioﬁlms more effectively than the culture methods that
we used.
25,26
The Oxford hip and knee scores have not, to our knowledge,
been used previously to assess outcome of revision surgery.
Nevertheless, these scores are well-validated patient-reported
outcome measures
14 and have been adopted by the NHS in
England for universal outcome assessment. Categories for the
Oxford hip score have been developed based on the Harris hip
score,
27 suggesting .41 excellent, 34–41 good, 27–33 fair
and ,27 poor. However, these scores relate to outcome follow-
ing primary hip replacement. Hence, a median score of 27 follow-
ing a two-stage revision for infection might be considered an
acceptable outcome, although we do not have baseline hip
and knee scores prior to revision.
Reimplantation cultures were positive surprisingly often
(14%), but the organism cultured was frequently unrelated to
the organisms cultured at excision, as in previous, smaller
studies.
28–30 At reimplantation, knee joints were more often
culture positive than hip joints, despite being less frequently
culture positive at the ﬁrst-stage excision. Spacers were used in
all of the knee joint revisions, but rarely in hips (13%), and may
contribute to the higher positive culture rate. Reimplantation
microbiology did not correlate with ﬁrst-stage microbiology,
further suggesting that the organisms were acquired at excision.
However, there seemed to be few clinical consequences of posi-
tive cultures, albeit in the context of broad-spectrum iv anti-
biotics prior to reimplantation, a low incidence of uncontrolled
infection and antibiotic treatment of most positive cultures at
reimplantation. Nevertheless, taking these ﬁndings together
with our previous observations in DAIR that prolonged antibiotics
beyond 6 months were of little beneﬁt,
15 it seems difﬁcult to
justify similarly prolonged courses of antibiotics for microbiologi-
cal results of uncertain signiﬁcance. Furthermore, our evidence
does not support the use of an antibiotic-free period as a test
of clinical cure, since the risk of requiring unplanned debridement
was highest during the period of antibiotic use, rather than
during the antibiotic-free period before reimplantation.
In conclusion, we report a success rate of 83% over a median
follow-up of 5.75 years, comprising success rates of 89% for ﬁrst
revisions and 73% for re-revision. Culture-negative infection was
common among these chronic infections treated by two-stage
revision, but was not associated with a worse outcome. Cultures
taken at reimplantation following an antibiotic-free period did
not predict outcome and clinical failure of treatment was more
often identiﬁed during antibiotic treatment than after antibiotics
were stopped. Reimplantation may be considered without an
antibiotic-free period, with additional antibiotic prophylaxis
before reimplantation.
31 Where multiple reimplantation cultures
are positive in the absence of clinical indicators of ongoing infec-
tion, a limited course of oral antibiotics may be appropriate.
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